AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role

Injection Cut Risk By 50%

 
• By Andrew McConaghie
  
AstraZeneca biologics
AstraZeneca's 600mg intramuscular dose is much lower than rival IV therapies, which should make hitting production easier, but the company is not disclosing its manufacturing targets.

More from COVID-19

More from Scrip